IVEVF News and Press, Inventiva SA From 03/07/24

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Other sites and count...

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million 2 , and long-term deposit at €9.0 million 3 as of December 31, 2023, compared to...

Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients wit...

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine which is expected to occur...

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects to have met the operational and financial conditions precedent to draw the second €25...

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for mor...

Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million 2 , and long-term deposit at €5.0 million 3 as of September 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively ...

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  ...

2023-09-29 14:58:08 ET Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Conference Call September 29, 2023, 08:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Michael Cooreman - Chief Medical Officer Conference Call Participants Ed ...

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 1 , and long-term deposit at €9.3 million 2 , as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivel R...